Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news : Millendo Therapeutics

10/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
30/09/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
25/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
22/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/03/21	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
29/03/21	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
28/01/21	Millendo Therapeutics, Inc. Announces Executive Changes	CI
28/01/21	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

06/01/21	MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
06/01/21	MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
09/11/20	MILLENDO THERAPEUTICS : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

24/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
16/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
LONZA GROUP AG	+0.84%	-0.74%	+3.78%	+15.46%	48.57B
REVOLUTION MEDICINES, INC.	+0.41%	+3.78%	+443.85%	+572.84%	41.95B
IQVIA HOLDINGS INC.	-2.68%	-3.18%	+29.72%	+4.99%	38.85B
BEONE MEDICINES AG	-0.02%	+1.90%	+9.94%	+75.02%	37.24B
CELLTRION, INC.	+2.47%	+8.33%	+15.16%	+48.37%	30.67B
MEDPACE HOLDINGS, INC.	-1.20%	+0.50%	+35.05%	+123.20%	16.41B
ASCENDIS PHARMA A/S	+2.27%	-0.47%	-	-	16.1B
EUROFINS SCIENTIFIC SE	+0.29%	+1.87%	+8.17%	+19.01%	13.97B
ICON PUBLIC LIMITED COMPANY	-1.29%	-3.21%	+3.08%	-36.32%	12.62B
Average	-1.37%	-0.30%	+68.59%	+102.82%	28.48B
Weighted average by Cap.	+0.14%	+0.39%	+89.56%	+129.35%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company